Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The objective is to compare the efficacy and safety of masitinib in combination with riluzole
versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral
Sclerosis (ALS).